ClinicalTrials.gg

Program

Everolimus

Also written as “everolimus”, “RAD001” and “Everolimus (RAD001)”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Tuberous Sclerosis · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors, led by 4 companies.

Furthest: phase 4, since Sep 8, 2005125 company-led studies, 2 open or runningNext primary completion: Feb 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis1201 open or runningphase 4since Sep 8, 2005Oct 6, 2004Feb 26, 2027phase 3 · NCT02962414
Chong Kun Dang Pharmaceutical21 open or runningphase 4since Apr 29, 2021Apr 29, 2021Dec 2030phase 4 · NCT06942156
iOMEDICO20 open or runningphase 4since Dec 23, 2010Dec 23, 2010none ahead
Chiesi Farmaceutici10 open or runningphase 2since Oct 28, 2016Oct 28, 2016none ahead

Also a collaborator on its studies: Merck, Pfizer, cromsource and roche-pharma-ag.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Nov 2, 2009.

  1. Feb 20, 2014Phase 2 study in Advanced Breast CancerNovartis · NCT02069093 · 92 enrolled · United States
  2. Mar 20, 2014Phase 3 study in Liver TransplantationNovartis · NCT02115113 · 78 enrolled · Italy
  3. Aug 28, 2014Phase 4 study in Breast NeoplasmsiOMEDICO · NCT02248571 · 85 enrolled · Germany
  4. Dec 1, 2014Phase 4 study in Body WeightNovartis · NCT02338609 · 15 enrolled · United States, Belgium, Russian Federation
  5. Jun 1, 20162 phase 4 studiesNovartis · NCT02864706, NCT02842749
  6. Oct 28, 2016Chiesi Farmaceutici's first study: phase 2 study in Kidney TransplantationNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT02970630 · 28 enrolled · Italy
  7. Nov 9, 2016Phase 3 study in Tuberous SclerosisNovartis · NCT02962414 · 206 enrolled · United States, Australia, Belgium and more
  8. Jun 1, 2017Phase 3 study in Breast NeoplasmsNovartis · NCT03176238 · 235 enrolled · Australia, India, Indonesia and more
  9. Sep 15, 2017Phase 2 study in Breast NeoplasmsNovartis · NCT03312738 · 159 enrolled · China
  10. May 3, 2018Phase 4 study in AngiomyolipomaNovartis · NCT03525834 · 40 enrolled · China
  11. Apr 29, 2021Chong Kun Dang Pharmaceutical's first study: phase 4 study in Liver TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT04867720 · 112 enrolled · Korea, Republic of
  12. Feb 16, 2022Phase 4 study in AngiomyolipomaNovartis · NCT05252585 · 10 enrolled · Taiwan
  13. Apr 11, 2025Phase 4 study in Heart TransplantChong Kun Dang Pharmaceutical · NCT06942156 · 140 planned · Korea, Republic of
  14. Nov 12, 2026Primary completion moved from 2026-12-30 to 2027-02-26Date moved laterphase 3 · +2 months · NCT02962414

Ahead

  1. Feb 26, 2027Primary completion: phase 3 study in Tuberous SclerosisNovartis · NCT02962414
  2. Dec 2030Primary completion: phase 4 study in Heart TransplantChong Kun Dang Pharmaceutical · NCT06942156

TargetBeta

FKBP1A →read by rule
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on FKBP1A

ProgramCompanyFurthest phaseStudies
TacrolimusruleAstellas Pharmaphase 4182

Studies

The newest 60 of 125 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06942156Heart Transplant · Korea, Republic of4Not yet recruitingChong Kun Dang PharmaceuticalDec 2030140
NCT05252585Angiomyolipoma · Taiwan4CompletedNovartisOct 13, 202610
NCT04867720Liver Transplant · Korea, Republic of4UNKNOWNChong Kun Dang PharmaceuticalOct 10, 2022112
NCT03525834Angiomyolipoma · China4CompletedNovartisSep 25, 202040
NCT03312738Breast Neoplasms · China2CompletedNovartisApr 25, 2022159
NCT03176238Breast Neoplasms · Australia, India, Indonesia and more3CompletedNovartisJan 29, 2019235
NCT02962414Tuberous Sclerosis · United States, Australia, Belgium and more3Active, not recruitingNovartisFeb 26, 2027206
NCT02970630Kidney Transplantation · Italy2CompletedChiesi FarmaceuticiFeb 22, 201828
NCT02842749Pancreatic Neuroendocrine Tumors · China4CompletedNovartisFeb 22, 202461
NCT02864706Graft vs Host Disease · Denmark, Norway, Sweden4CompletedNovartisSep 25, 201795
NCT02338609Body Weight · United States, Belgium, Russian Federation4CompletedNovartisDec 18, 202315
NCT02248571Breast Neoplasms · Germany4CompletediOMEDICOAug 31, 201785
NCT02115113Liver Transplantation · Italy3CompletedNovartisSep 30, 201678
NCT02069093Advanced Breast Cancer · United States2CompletedNovartisMar 201692
NCT02017860Neoplasms · Japan2CompletedNovartisApr 25, 20194
NCT01843348Rejection, Psychology · France, Germany3CompletedNovartisMar 23, 2016612
NCT01789281Neoplasms · United States, Czechia, Italy and more4CompletedNovartisAug 28, 202034
NCT01783444Breast Neoplasms · United States, Argentina, Australia and more2CompletedNovartisJul 2, 2018309
NCT01743560Breast Neoplasms · United Kingdom4CompletedNovartisAug 15, 201652
NCT01713946Tuberous Sclerosis Complex-associated Refractory Seizures · United States, Argentina, Australia and more3CompletedNovartisOct 25, 2017366
NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more2CompletedNovartisDec 17, 2015202
NCT01626222Breast Neoplasms · Germany3CompletedNovartisNov 2013301
NCT01625377Liver Transplantation · France3CompletedNovartisMar 2015188
NCT01595009Neuroendocrine Tumors · Germany4CompletedNovartisAug 9, 2016246
NCT01594268Kidney Transplant · Korea, Republic of4CompletedNovartisOct 201354
NCT01590199Neuroendocrine Tumors · Germany1CompletedNovartisSep 11, 201818
NCT01563354Carcinoma, Neuroendocrine · Denmark, France, Germany and more2CompletedNovartisFeb 10, 2020124
NCT01551212Liver Transplantation · Germany4CompletedNovartisAug 8, 2017339
NCT01514448Carcinoma, Renal Cell · Germany4CompletedNovartisApr 1, 201629
NCT01524783Neuroendocrine Tumors · United States, Austria, Belgium and more3CompletedNovartisNov 28, 2014302
NCT01491672Carcinoma, Renal Cell · United States, Argentina, Brazil and more2CompletedNovartisMay 2015134
NCT01545817Carcinoma, Renal Cell · Australia, Korea, Republic of2TerminatedNovartisNov 18, 201674
NCT01596062Renal Transplantation · France2CompletedNovartisMar 201316
NCT01404325Lung Transplantation · Germany3CompletedNovartisJan 5, 2017130
NCT01374451Adenoma, Islet Cell · United States, Argentina, Australia and more2TerminatedNovartisFeb 2015160
NCT01544491Death · United States, Argentina, Brazil and more3CompletedNovartisOct 3, 2016106
NCT01379521Carcinoma, Hepatocellular · Hong Kong, Taiwan, Thailand2TerminatedNovartisJun 201565
NCT01365468Neurofibroma, Plexiform · Israel2TerminatedNovartisApr 20159
NCT01324492Lung Neuroendocrine Neoplasm · China1CompletedNovartisJun 201416
NCT01317615Carcinoma, Large Cell · Germany4CompletedNovartisMar 201549
NCT01275222Gastrointestinal Stromal Tumors · United States, Belgium, France and more2CompletedNovartisSep 3, 2008117
NCT01266837Carcinoma, Renal Cell · Germany4CompletediOMEDICOSep 26, 201764
NCT01263353Carcinoid Tumor · Germany1CompletedNovartisMar 201436
NCT01231659Breast Neoplasms · Israel2CompletedNovartisNov 20, 201272
NCT01217177Uterine Cervical Neoplasms · Brazil1CompletedNovartisApr 201414
NCT01269684Kidney Transplantation · Switzerland4WithdrawnNovartisAug 20080
NCT01206764Carcinoma, Renal Cell · Algeria, Egypt, India and more4CompletedNovartisJun 6, 2017143
NCT01266148Renal Function and Chronic Allograft Vasculopathy · Denmark, Norway, Sweden4CompletedNovartisDec 2012115
NCT01169701Hypertrophy, Left Ventricular · Spain4CompletedNovartisMar 201471
NCT01152801Carcinoma, Renal Cell · China1CompletedNovartisDec 201364
NCT01114529Kidney Transplantation · Argentina, Australia, Austria and more3CompletedNovartisOct 30, 2014828
NCT01150097Liver Transplant Recipient · United States, Argentina, Australia and more3CompletedNovartisMay 3, 2013284
NCT01079143Renal Interstitial Fibrosis · France3CompletedNovartisJun 2012194
NCT01059318Lymphangioleiomyomatosis · United States, France, Italy2CompletedNovartisJun 201224
NCT01035229Carcinoma · United States, Australia, Austria and more3CompletedNovartisOct 2013546
NCT01023815de Novo Kidney Transplant Recipients · Italy3CompletedNovartisJul 2012330
NCT01022996Hodgkin Disease · United States2CompletedNovartisNov 201457
NCT01025817Kidney Transplant · United States, Canada3CompletedNovartisMar 2013613
NCT01017029Cardiac Transplantation · Italy4CompletedNovartisDec 2013182
NCT01007942Breast Neoplasms · United States, Argentina, Australia and more3CompletedNovartisJun 2015569

How it is read

Names in the registry

  • “Everolimus”, 64 entries
  • “everolimus”, 16 entries
  • “RAD001”, 16 entries
  • “Everolimus (RAD001)”, 15 entries
  • “Everolimus (reduced tacrolimus)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.